Brainsway Ltd. Partners with Neurolief for Strategic Investment in Proliv™Rx System Launch for Major Depressive Disorder
Brainsway Ltd. has partnered with Neurolief to invest strategically in the launch of the Proliv™Rx system for treating Major Depressive Disorder. This collaboration aims to utilize Brainsway's commercial expertise to support Neurolief's FDA approval process and the scaling of its innovative at-home treatment solution. Both companies focus on enhancing access to non-invasive mental health treatments for patients unresponsive to traditional therapies.
Brainsway Ltd., a leading company in non-invasive neurostimulation treatments for mental health disorders, has entered into a strategic partnership with Neurolief, a pioneering brain stimulation company specializing in non-invasive neuromodulation therapies. This collaboration involves BrainsWay making a strategic investment in Neurolief as the latter awaits FDA approval for its Proliv™Rx system, which is designed to treat Major Depressive Disorder (MDD). The partnership aims to leverage BrainsWay’s commercial expertise and extensive global reach to support the anticipated launch and scaling of Neurolief’s innovative at-home treatment solution for MDD. Both companies are committed to expanding access to cutting-edge, non-invasive mental health treatments, addressing the unmet needs of patients who have not responded adequately to traditional therapies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainsway Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: FL55872) on August 21, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
